See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Baseball
Natural Disasters
Education
Social Media
Republican Party
Democratic Party
Senate
Taxes
Artificial Intelligence
Tariffs
Donald Trump
Soccer
Published • loading... • Updated

Study Concludes Total Joint Arthroplasty Is Safe for Patients With a History of Atrial Fibrillation

Summary by Medscape
‘Very reassuring’ data for outpatient procedures, according to a new study. Medscape Medical News

7 Articles

All
Left
Center
Right
Clinical Trials ArenaClinical Trials Arena

ACC 25: GLP-1 receptor agonists emerge for treating atrial fibrillation

There is an increasing demand for GLP-1RAs across the spectrum of cardiometabolic disease.The post ACC 25: GLP-1 receptor agonists emerge for treating atrial fibrillation appeared first on Clinical Trials Arena.

Read Full Article
myscience.orgmyscience.org

More effective treatment for atrial fibrillation: new inter-vention method shows promising results

31.03.2025 - Atrial fibrillation is the most common cardiac arrhythmia worldwide. While exist-ing interventional treatment methods, such as catheter ablation, work better than medication, they still have their limitations and risks. In a recent study led by the Inselspital, Bern University Hospital, the University of Bern, and the Basel University Hospital, a new treatment method is now showing pr

Read Full Article
MedscapeMedscape

Study Concludes Total Joint Arthroplasty Is Safe for Patients With a History of Atrial Fibrillation

‘Very reassuring’ data for outpatient procedures, according to a new study. Medscape Medical News

·United States
Read Full Article
Managed Healthcare ExecutiveManaged Healthcare Executive

Abelacimab Shows Promise in Reducing Bleeding Risks for High-Risk Patients

In an interview with Managed Healthcare Executive, Christian T. Ruff, M.D., M.P.H., director of general cardiology at Brigham and Women's Hospital and associate professor at Harvard Medical School, addressed the uncertainty of the bleeding risks of abelacimab compared to rivaroxaban and highlighted abelacimab’s safety profile.

Read Full Article
ajmc.comajmc.com

Abelacimab Shows Unprecedented Bleeding Risk Reduction in Patients With Atrial Fibrillation

Christian T. Ruff, MD, MPH, of Brigham and Women's Faulkner Hospital, discusses new data comparing abelacimab with rivaroxaban in patients with atrial fibrillation presented at the American College of Cardiology 2025 Annual Scientific Session.

Read Full Article
ADKhabarADKhabar

Anthos Therapeutics Shares New Data from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age or Bleeding Risk

–Data presented at the American College of Cardiology Annual Scientific Session show that the reduction of bleeding with abelacimab compared to rivaroxaban (Xarelto) was even greater in patients ≥75 years old compared to younger patients –Another analysis from AZALEA-TIMI 71 shows abelacimab, as compared to rivaroxaban (Xarelto), was associated with a greater absolute benefit in […]

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Pharmacy Times broke the news in on Sunday, March 30, 2025.
Sources are mostly out of (0)

Similar News Topics

Medical

Medical

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal